Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 1997

View Archived Issues

87 development projects under way at Zeneca

New AmBisome data reported

SmithKline Beecham licenses rotavirus vaccine

Faropenem data presented at Japanese congress

Searle describes selective alphav/beta3 integrin antagonists

Natural anti-HIV agent disclosed by Hoechst

ViroPharma develops agents for HCV infection

5-HT receptor (ant)agonists from Pfizer

Selective COX-2 inhibitors under development at Merck Frosst

Second-generation antisense antitumor compound from Hybridon enters clinic

Aronex presents preliminary phase II results on Atragen

Pennsaid submitted to FDA for approval

CerAxon submitted for approval in U.S.

CB1 receptors are activated in hemorrhagic shock

FDA approves new alternative to hysterectomy in women with menorrhagia

Promising results reported from phase II trial for AIDS-related diarrhea

Oral morphine effective for management of sickle cell pain in children

ICAgen and Abbott join forces for ion channel research

Spotlight on ACE inhibitor/calcium antagonist combinations

Sagami discovers lead for potent and selective anti-H. pylori agents

Itraconazole maintenance therapy prevents relapse of histoplasmosis in AIDS

rhIL-11 reduces need for platelet transfusion in breast cancer patients on high-dose chemotherapy

Scherer-Sankyo Zydis formulation agreement

Orally activated protein therapy reported

Elan to acquire Sano in all-stock transaction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...